United Therapeutics sued HHS and HRSA on June 23 over 340B contract pharmacy requirements.

Sixth Drug Manufacturer Sues HHS and HRSA Over 340B Contract Pharmacy

Drug manufacturer United Therapeutics (UT) has sued the federal government over its 340B contract pharmacy requirements, saying it is being forced “to engage in a program that enriches national pharmacy corporations at UT’s direct expense and at the expense of the intended beneficiaries of Congress’s program.”

UT joins fellow drug makers AstraZeneca, Eli Lilly, Novartis, Novo Nordisk, and Sanofi, each of which is individually suing the U.S. Health and Human Services Department (HHS) and the U.S. Health Resources and Services Administration over HRSA’s 340B contract pharmacy policies.

Drug manufacturer United Therapeutics (UT) has sued the federal government over its 340B contract pharmacy requirements, saying it is being forced “to engage in a program that enriches national pharmacy corporations at UT’s direct expense and at the expense of the intended beneficiaries of Congress’s program.”

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer